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Effect of continuous statistically standardized
measures of estrogen and progesterone
receptors on disease-free survival in NCIC CTG
MA.12 Trial and BC Cohort
Judith-Anne W Chapman1*, Torsten O Nielsen2, Matthew J Ellis3, Phillip Bernard4, Stephen Chia5, Karen A Gelmon5
, Kathleen I Pritchard6, Aurelie Le Maitre1, Paul E Goss7, Samuel Leung2, Lois E Shepherd1 and
Vivien H C Bramwell8
Abstract
Introduction: We hypothesized improved inter-laboratory comparability of estrogen receptor (ER) and
progesterone receptor (PgR) across different assay methodologies with adjunctive statistical standardization, akin to
bone mineral density (BMD) z-scores. We examined statistical standardization in MA.12, a placebo-controlled pre-
menopausal trial of adjuvant tamoxifen with locally assessed hormone receptor +/- tumours, and in a cohort of
post-menopausal British Columbia (BC) tamoxifen-treated patients.
Methods: ER and PgR were centrally assessed for both patient groups with real time quantitative reverse
transcription polymerase chain reaction (qPCR) and immunohistochemistry (IHC). Effects on disease-free survival
(DFS) were investigated separately for 345 MA.12 and 673 BC patients who had both qPCR and IHC assessments.
Comparisons utilized continuous laboratory units and statistically standardized z-scores. Univariate categorization of
ER/PgR was by number of standard deviations (SD) above or below the mean (z-score ≥1.0 SD below mean; z-
score <1.0 SD below mean; z-score ≤1.0 SD above mean; z-score >1.0 SD above mean). Exploratory multivariate
examinations utilized step-wise Cox regression.
Results: Median follow-up for MA.12 was 9.7 years; for BC patients, 11.8 years. For MA.12, 101 of 345 (29%) patients
were IHC ER-PgR-. ER was not univariately associated with DFS (qPCR, P = 0.19; IHC, P = 0.08), while PgR was
(qPCR, P = 0.09; IHC, P = 0.04). For BC patients, neither receptor was univariately associated with DFS: for ER, PCR, P
= 0.36, IHC, P = 0.24; while for PgR, qPCR, P = 0.17, IHC, P = 0.31. Multivariately, MA.12 patients randomized to
tamoxifen had significantly better DFS (P = 0.002 to 0.005) than placebo. Meanwhile, jointly ER and PgR were not
associated with DFS whether assessed by qPCR or by IHC in all patients, or in the subgroup of patients with IHC
positive stain, for pooled or separate treatment arms. Different results by type of continuous unit supported the
concept of ER level being relevant for medical decision-making. For postmenopausal BC tamoxifen patients, higher
qPCR PgR was weakly associated with better DFS (P = 0.06).
Conclusions: MA.12 pre-menopausal patients in a placebo-controlled tamoxifen trial had similar multivariate
prognostic effects with statistically standardized hormone receptors when tumours were assayed by qPCR or IHC,
for hormone receptor +/- and + tumours. The BC post-menopausal tamoxifen cohort did not exhibit a significant
prognostic association of ER or PgR with DFS. Adjunctive statistical standardization is currently under investigation
in other NCIC CTG endocrine trials.
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Introduction
The growth of many breast cancers is hormone-
dependent, with estrogen receptor (ER) and/or proges-
terone receptor (PgR) expression a prerequisite for
responsiveness to endocrine therapy. Increased aware-
ness about uncertainties in accurate assessment of these
pivotal breast cancer biomarkers has renewed interest in
standardization; there is the potential that 20% of
current immunohistochemical (IHC) assay results world-
wide are either false negatives or false positives [1].
Aspects affecting assays include tumor heterogeneity,
acquisition and processing of specimens, antibody
choices, laboratory assessment protocols, reproducibility
of procedures, external assessment of process, profi-
ciency of laboratory workers, sufficiency of scoring posi-
tivity and cut-points for positivity [1]. The American
Society of Clinical Oncology and the College of
American Pathologists (ASCO/CAP) recently published
guideline recommendations for IHC testing of ER and
PgR in breast cancer [1]. The Panel recommended a
cut-off of a minimum of 1% of tumor cells positive for
ER/PgR for a specimen to be considered positive [1].
Chia et al. [2] centrally assessed ER and PgR in the
NCIC Clinical Trials Group Breast Committee Mammary
(MA).12 (NCIC CTG MA.12) placebo-controlled trial of
tamoxifen in premenopausal women; they utilized the
new 1% cut-off for IHC positivity to examine the prog-
nostic and predictive associations of ER and PgR with
relapse-free and overall survival. Neither hormone recep-
tor was found to be prognostic or predictive. However,
intrinsic subtyping by PAM50 was prognostic and lumi-
nal subtypes were predictive of benefit from tamoxifen.
Welsh et al. focused standardization of ER assessments
on the determination of ER positivity using automated
quantitative immunofluorescence (QIF) [3] which has a
broader range of detection than IHC, possibly minimizing
false negative results. Cell lines with ER immunoreactivity
were analyzed with QIF for standardization reliant on
threshold intensity. Cut-offs at 10% or 1% did not greatly
alter the proportion of positive tumours [3]. Further, Iwa-
moto et al. found that the small number of patients with
1% to 9% positive tumours is molecularly similar to ER-
positive patients [4].
Bartlett et al. [5] investigated the role of continuous
ER and PgR with the Tamoxifen and Exemestane Adju-
vant Multinational (TEAM) trial data. They found sig-
nificant prognostic effects with increasing values of
continuous ER and PgR associated with higher disease-
free survival (DFS) in the short (maximum 2.75 years)
follow-up period before tamoxifen patients switched to
exemestane [5].
We hypothesized that the process of statistical stan-
dardization originally envisaged to improve inter-labora-
tory comparability of ER/PgR assay results might be
useful to improve comparability of results between assay
methods. We investigate here the association of contin-
uous ER and PgR with DFS in patients randomized to
tamoxifen or placebo regardless of locally determined
ER and PgR tumour status. Central review permitted
investigation of statistical standardization for IHC and
qPCR assessment modalities [6-10] across a broad range
of hormone receptor values.
Methods
Patients
NCIC CTG MA.12
NCIC CTG MA.12 was a placebo-controlled trial of
tamoxifen therapy following adjuvant chemotherapy in
premenopausal women with early breast cancer [11]
[see Additional file 1 CONSORT Diagram]. The study
was approved by local research Ethics Boards, and
patients provided written informed consent [11]. The
NCIC CTG MA.12 Study Chair (VHCB), Physician
Coordinator (LS) and sources of qPCR and IHC hor-
mone receptor data (TON, SC, PB, MJE) gave permis-
sion to use MA.12 data in this work.
Patients with pathological T1-4, N0-2, M0 tumours
were eligible. Local centre determination of levels of at
least one hormone receptor (ER and/or PgR), by bio-
chemical (positive ≥10 fmol/mg protein) or immunohis-
tochemical assay was required, but patients with any
receptor status were eligible. The stratification factors
were type of chemotherapy (cyclophosphamide, metho-
trexate and fluorouracil (CMF); cyclophosphamide, epir-
ubicin, fluorouracil (CEF); doxorubicin (adriamycin)/
cyclophosphamide (AC)), hormone receptor status (ER
and/or PgR positive, ER and PgR negative) and nodal
status (0, 1 to 3, 4 to 9, 10+). The primary endpoint was
overall survival (OS). DFS was a secondary endpoint and
was defined as being the time from randomization to
the earliest date of recurrence or death; censoring was
the last date the patient was known to be alive.
A total of 672 women were accrued to MA.12, 338
randomized to tamoxifen and 334 to placebo. Tumour
hormone receptor status was positive in 505 (75%) of
women. At 9.7 years median follow-up, multivariate
analysis showed a DFS benefit for tamoxifen of border-
line significance (P = 0.056) and a trend for improved
OS (P = 0.12). There was no evidence of greater efficacy
for tamoxifen in the hormone-receptor positive or ER
receptor-positive subgroups than in hormone-receptor
negative or ER receptor-negative patients: interaction
test P -values were, respectively, 0.71 and 0.14.
The process of statistical standardization requires con-
tinuous assay assessments, assessed by the same assess-
ment method, in the same laboratory, under similar
circumstances, for a sufficient number of patients to
characterize the assay results with a normal distribution.
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The 672 MA.12 patients were accrued at 44 Canadian
centres, with multiple different laboratories assaying
tumours for hormone receptor status. Further, many of
the patients entered MA.12 following biochemical assay
of ER/PgR or with IHC results categorized as positive or
negative. Thus, the local hormone receptor data were
not suitable for our investigations. MA.12 patients with
ER and PgR centrally assessed by qPCR and IHC did
not apparently differ in baseline characteristics from all
patients randomized to the trial [2].
British Columbia patient cohort
Adjuvant endocrine therapy would currently be considered
for patients assessed to have hormone receptor positive
tumours, regardless of menopausal status. Our investiga-
tions were augmented here with a cohort of 767 British
Columbia breast cancer patients [12] who had central
assessment of ER and PgR in the same laboratory as the
MA.12 patients. The BC patients were all women with new
primary breast cancer, who received adjuvant tamoxifen,
without adjuvant chemotherapy. Only 22 of the patients
were pre-menopausal, and 11 had unknown menopausal
status, so we restricted investigations to the post-menopau-
sal patient group. We defined a MA.12 DFS endpoint for
the BC patients as time from randomization to the earliest
date of recurrence or death, censoring at the last date the
patient was known to be alive, or if alive, at June 30, 2004.
Central review
ER and PgR were centrally assessed in the laboratory of
TN by real time quantitative RT-PCR (qRT-PCR) and
by IHC. Following pathologist review of formalin-fixed,
paraffin-embedded source blocks stored at the NCIC-
CTG Pathology office, two 0.6 mm cores were removed
from representative areas of viable invasive carcinoma
for tissue microarray construction, and two 1.0 mm
cores were removed for RNA purification and qPCR
determination of ER (ESR1) and PR (PGR) using the
PAM50 assay method [12]. IHC analyses were per-
formed on 4-micron sections from the tissue microarray,
with ER assessed using ASCO/CAP compatible methods
[1] (MA.12 trial: SP 1 rabbit monoclonal antibody
(ThermoFisher Scientific, Fremont, CA, USA), using
1:50 dilution for 32 minutes with heat, and mild CC1
on Ventana BenchMark. PgR was similarly assessed with
rabbit monoclonal 1E2 (Ventana, Tuscon, AZ, USA),
pre-diluted for eight minutes with heat, and standard
CC1 antigen retrieval and incubation; BC cohort: 6F11
mouse monoclonal antibody (Leica Biosystems Newcas-
tle Ltd, UK), using 1:50 dilution for two hours with no
heat, and standard CC1 on Ventana Dixcovery XT)). ER
and PgR IHC were assessed by a pathologist as a visual
score from 0 to 100% based on the fraction of invasive
cancer nuclei positive above background.
Statistical methods
ER and PgR qPCR data were log2 transformed; labora-
tory ER and PR zeros were treated as missing. Mean-
while, for ER and PgR IHC% positive stain, the Box-Cox
loge transformation was indicated for variance stabiliza-
tion, after addition of 0.1 to IHC ER and PgR zeros to
permit the transformation. For each hormone receptor
assessment method, the continuous logarithmic values
were converted to statistically standardized z-scores
using the assessment method mean and SD of logarith-
mic values:
z- score = ((log value - mean of log values)÷SD of log
values), which has approximately a standard normal dis-
tribution, N(0,1).
For comparability, DFS investigations included
patients who had both ER and PgR assays, by both
qPCR and IHC. With the MA.12 trial, we investigated
the effects of ER and PgR for: 1) all women regardless
of ER and PgR status, referred to hereafter as all
patients; and 2) the subgroup of these patients with cen-
trally confirmed positive IHC staining for ER and/or
PgR tumours; for patients allocated to 1) placebo, 2)
tamoxifen or 3) both arms together. All the BC postme-
nopausal patients received tamoxifen and were assessed
as a single group.
DFS was the endpoint utilized here to investigate the
association between ER and PgR and outcome. Univariate
tests for MA.12 utilized the stratified log-rank statistic;
for the BC cohort, we used the generalized Wilcoxon
(Peto-Prentice) test statistic. Graphical description was
with Kaplan-Meier plots. For MA.12, we plotted the
experience for IHC ER/PR zero and for ER/PgR positive
stain, while for the BC group all patients were IHC ER
positive. Analogous to bone mineral density (BMD), we
used cut-points for positive stain categorization of num-
ber of standard deviations (SD) above/below the mean
(z-score ≥1.0 SD below mean; z-score <1.0 SD below
mean; z-score ≤1.0 SD above mean; z-score >1.0 SD
above mean).
Exploratory multivariate examinations were with
adjusted Cox regression, stratified for MA.12 by the
stratification factors of nodal status and chemotherapy
type. We investigated the effects of ER and PgR in
continuous laboratory and statistically standardized
z-scores. To permit comparison across assessment
methods, ER and PgR had forced inclusion in all mod-
els, while for MA.12 trial therapy and baseline patient
characteristics (age, pathological stage, pathological T
stage, ECOG performance) were added in step-wise
mode (P ≤0.05). Factors considered for the BC cohort
were age, MA.12 categories for number of positive
nodes and clinical T stage; none of the patients
received adjuvant chemotherapy.
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Results
MA.12 patients
Of the 672 MA.12 patients, centrally assessed ER was
available by IHC for 392 (58%) and for PgR, for 376
(56%) patients. There were 124 centrally reviewed
patients with no IHC staining for ER or PgR. Centrally
assessed ER was available by qPCR for 385 (57%)
patients and for PgR for 389 (58%). Figure 1 shows the
qPCR ER assay results for all patients; Figure 2, the
qPCR ER results for central IHC positive hormone
receptor stain; Figure 3, the qPCR PgR results for all
patients; and Figure 4, the qPCR PgR results for central
IHC positive hormone receptor stain. Histograms of
qPCR ER and PgR values in Figures 1 and 3 covered the
spectrum of negative and positive IHC stain and exhib-
ited bimodality. Meanwhile, qPCR values for tumours
with only positive IHC stain in Figures 2 and 4 exhibit
unimodal distributions. Corresponding IHC histograms
are provided [see Additional files 2 to 5, Figures S1 to
S4]; the best Box-Cox transformation was a logarithm,
although the resulting IHC histograms do not indicate
the same level of symmetry as those observed for qPCR.
To have the same patients included in comparisons
across assessment methods, all further examinations
were restricted to the group of 345 patients who had
both ER and PgR assessed by both qPCR and IHC; 101
(29%) of these patients had tumours with no IHC stain
for ER or PgR. The K-M plots (Figures 5 to 8) depict
DFS experience for patients whose tumours under cen-
tral review had no IHC ER or PgR staining, and DFS
experience for ER or PgR assay results categorized by
Figure 1 Histogram of the NCIC CTG MA.12 qPCR (log2) ER
assay results for all patients: N = 385. ER, estrogen receptor.
Figure 2 Histogram of the NCIC CTG MA.12 qPCR (log2) ER
results for central IHC ER and/or PgR >0: N = 263. ER, estrogen
receptor; IHC, immunohistochemistry; PgR, progesterone receptor.
Figure 3 Histogram of the NCIC CTG MA.12 qPCR (log2) PgR
results for all patients: N = 389. PgR, progesterone receptor.
Figure 4 Histogram of the NCIC CTG MA.12 qPCR (log2) PgR
results for IHC ER and/or PgR >0: N = 262. ER, estrogen receptor;
IHC, immunohistochemistry; PgR, progesterone receptor.
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their Z-scores to be multiple SDs above or below the
mean: greater to or equal to 1 SD below mean, less than
1SD below the mean, less than or equal to 1 SD above
the mean, and greater than 1 SD above the mean. Uni-
variately, qPCR ER was not associated with DFS (Figure
5, P = 0.19), while both qPCR PgR (Figure 6, P = 0.09)
and IHC ER (Figure 7, P = 0.08) had weak evidence of
association, and IHC PgR (Figure 8) achieved statistical
significance (P = 0.04). There was a general indication
that patients with ER and PgR staining z-score values
>1.0, that is, >1.0 SD above the standardized mean, had
better DFS, while those with no IHC ER and PgR stain
had worse DFS.
Multivariate results are provided in Table 1. In all
instances, patients randomized to tamoxifen had signifi-
cantly better DFS (P = 0.002 to 0.005) than those allo-
cated to placebo. However, patients randomized to the
tamoxifen arm did not have significantly different DFS
by ER or PgR levels, in continuous or standardized
units, whether assessed by qPCR or IHC, in all patients,
or in the subgroup of patients with IHC positive stain.
Likewise, with pooling of patients on both treatment
arms, there was no overall evidence for an association
for ER or PgR with DFS. The single instance of standar-
dized PgR being significant (P = 0.05) may easily be due
to chance with the number of tests performed.
There is inconsistent evidence of a prognostic effect
for hormone receptors for patients randomized to the
placebo arm. The evidence was strongest for qPCR
PgR (P = 0.01 to 0.04 in three of four scenarios). The
inconsistency is illustrated in two scenarios. For IHC
hormone receptor positive and negative patients,
laboratory value qPCR assessment alone indicated sig-
nificant association of PgR with DFS (P = 0.02) while
IHC alone indicated weak evidence for IHC PgR (P =
0.08). However, the joint consideration of laboratory
IHC and qPCR assessments led to a qPCR PgR P-value
of 0.15 (changed from 0.02) and IHC PgR P-value of
Figure 5 NCIC CTG MA.12 Disease Free Survival by Standardized qPCR ER: Assay results are categorized by their z-scores (greater to or
equal to 1 standard deviation (SD) below mean, less than 1 SD below the mean, less than or equal to 1 SD above the mean, and greater than
1 SD above the mean) or whether tumors under central review had no IHC assay staining. ER, estrogen receptor; IHC, immunohistochemistry.
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0.41 (changed from 0.08), with significant association
for continuous qPCR ER (P = 0.03, changed from P =
0.12) and weak evidence for IHC ER (P = 0.08, chan-
ged from P = 0.27). Thus, there is a reversed indication
of whether PgR or ER has the significant association
with DFS.
The second example occurs in the subgroup with
positive IHC hormone receptor stain. Laboratory qPCR
assessment alone indicated PgR was significantly asso-
ciated with DFS (P = 0.01), although in the joint consid-
eration of IHC and qPCR, both qPCR ER (P = 0.04) and
IHC ER (P = 0.01) were also significant. There was a
change from only PgR being significant to both ER and
PgR being significantly associated with DFS.
Further, substantive differences were noted on the pla-
cebo arm jointly considering both IHC and qPCR
between ER assessed with or without standardization:
for all patients regardless of IHC status, standardized
qPCR ER P = 0.12 versus laboratory units P = 0.03; with
positive IHC stain, standardized IHC ER, P = 0.21 ver-
sus laboratory units P = 0.01; standardized qPCR ER, P
= 0.11 versus laboratory units P = 0.04. There are differ-
ences in results by type of continuous unit supporting
the concept that level of ER beyond a dichotomous
negative or positive stain could be relevant for medical
decision-making.
BC patients
ER was centrally assessed by qPCR for 767 patients and
IHC for 688 patients; PgR by qPCR for 767 patients and
IHC for 717 patients. There were 673 of 767 (88%)
patients who had central qPCR and IHC for ER and PgR.
To have the same patients included in comparisons
across assessment methods, all further examinations were
restricted to this group of 673 patients, all of whom had
IHC stain for ER and/or PgR. The K-M plots (Figures 9
to 12) depict DFS experience for patients whose tumours
under central review had ER or PgR assay results
Figure 6 NCIC CTG MA.12 Disease Free Survival by Standardized qPCR PgR: Assay results are categorized by their z-scores (greater to or
equal to 1 standard deviation (SD) below mean, less than 1 SD below the mean, less than or equal to 1 SD above the mean, and greater than 1 SD
above the mean) or whether tumors under central review had no IHC assay staining. IHC, immunohistochemistry; PgR, progesterone receptor.
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categorized by their Z-scores to be multiple SDs above or
below the mean: greater to or equal to 1 SD below mean,
less than 1SD below the mean, less than or equal to 1
SD above the mean, and greater than 1 SD above the
mean. Univariately, qPCR ER was not associated with
DFS (Figure 9, P = 0.36), nor was qPCR PgR (Figure 10,
P = 0.17), IHC ER (Figure 11, P = 0.24) or IHC PgR
(Figure 12, P = 0.31). Similar to MA.12, there was a
general indication that patients with ER and PgR staining
z-score values >0., that is, those above the standardized
mean had better DFS, while those with no IHC ER and
PgR stain had worse DFS, although experience converged
to being similar by about 10 years.
Multivariate results are provided in Table 2. All patients
received adjuvant tamoxifen, without adjuvant chemother-
apy. There was no evidence that ER was associated with
DFS, and only weak multivariate evidence (P = 0.06) that
higher PgR was associated with better DFS.
Discussion
Breast cancer is a complex disease which displays both
inter-case and intra-tumour heterogeneity [13-16].
Tumor ER and/or PgR positivity is a prerequisite for
responsiveness to targeted therapy with an endocrine
agent. Yet, inter-laboratory comparability of hormone
receptor assay values is still problematic after decades of
routine clinical assessment. Many laboratories do not par-
ticipate in external quality assurance programs, and the
use of a uniform method of assessment is not assured
even for those that do [1,3,5,16-19]. Tumour levels of
hormone receptors, ER a and PgR, and dynamic range of
assessment methodology [3,20,21] impact indications for
the presence of hormone receptors. Further, while mar-
kers such as HER2 are quite homogeneously expressed
across a tumour, ER and, particularly, PgR [22] may be
more heterogeneous. Finally, the current multitude of
laboratory assessment methods, scoring and (prior to the
Figure 7 NCIC CTG MA.12 Disease Free Survival by Standardized IHC ER: Assay results are categorized by their z-scores (greater to or equal
to 1 standard deviation (SD) below mean, less than 1 SD below the mean, less than or equal to 1 SD above the mean, and greater than 1 SD
above the mean) or whether tumors under central review had no IHC assay staining. ER, estrogen receptor; IHC, immunohistochemistry.
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recent ASCO/CAP Guideline recommendations1) dichot-
omous cut-points for positivity from ‘any positivity’ to an
‘H-score of 50’ [23] have been problematic [24-27].
Part of the controversy about ER and PgR cut-points
for positivity has centred around the inability in most
endocrine clinical trials to assess the effects of therapy
in patients with false negative ER and PgR. NCIC CTG
MA.12 had the unusual feature of patients being rando-
mized to tamoxifen or placebo regardless of their locally
determined ER and PgR, permitting an examination of
the effects of endocrine therapy for the spectrum of hor-
mone receptor values.
Central review of ER and PgR with both qPCR and
IHC permitted a comparison of these two methods, as
well as a demonstration of benefit with higher levels of
ER and PgR positivity.
Lastly, statistical standardization within assessment
methods provided a common set of z-scores which
would be expected to improve inter-laboratory
comparability.
The comparison in this work was across methodologic
platforms since patients may now have ER and PgR
assessed clinically in a variety of ways, with different
intra-method variability as well as inter-laboratory varia-
bility by method. Differences for IHC alone were the sub-
ject of the ASCO/CAP guidelines1. PCR methods are
more quantitative, producing continuous assay levels;
however, there is a need to establish validity by level. We
restricted investigations here, achieved in the same
laboratory, to be for the same patients for both methods.
The methodology of categorizing ER- and PgR-posi-
tive stain by cut-points corresponding to z-score stan-
dard deviations (analogous to BMD studies) indicated
general univariate support that high levels of hormone
receptors led to better DFS, and no receptors to a worse
outcome. IHC PgR was significantly (P = 0.04)
Figure 8 NCIC CTG MA.12 Disease Free Survival by Standardized IHC PgR: Assay results are categorized by their z-scores (greater to or
equal to 1 standard deviation (SD) below mean, less than 1 SD below the mean, less than or equal to 1 SD above the mean, and greater than
1 SD above the mean) or whether tumors under central review had no IHC assay staining. IHC, immunohistochemistry; PgR, progesterone
receptor.
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associated with DFS while qPCR PgR (P = 0.09), qPCR
ER (P = 0.19), and IHC ER (P = 0.08) were not.
In the current study, IHC analyses for ER and PgR
had a stronger association with outcome than was seen
with single gene measurements for ESR1 and PGR.
Tamoxifen acts against the ER protein rather than its
mRNA so perhaps this result is not surprising. One
strength of qPCR over IHC is the ability to quantify
multiple genes simultaneously as a signature, allowing a
quantitative association of multi-gene expression with a
luminal centroid that is a stronger predictor of endo-
crine therapy response than single gene measures (Chia
SK et al. [2]). Here, we confined our study to single bio-
markers and focused particularly on IHC, the primary
diagnostic method used in current clinical practice.
In MA.12, we found inconsistent multivariate indica-
tions of prognostic effect for hormone receptors for
patients allocated to the placebo arm. High correlations
between ER and PgR likely influenced indications of sig-
nificance; for example, for all patients, when qPCR and
IHC were assessed separately, PgR significance was indi-
cated, qPCR PgR (P = 0.02) and IHC PgR (0.08). Mean-
while, in joint consideration of the two assessment
modalities, only qPCR ER (P = 0.03) was significantly
prognostic.
Likewise, for patients with positive IHC stain, qPCR
PgR (P = 0.01) was significant, although in joint exami-
nation we found qPCR PgR (P = 0.01) as well as qPCR
ER (P = 0.04) and IHC ER (P = 0.01) to be significantly
associated.
Previously, we saw indications that biochemical ER, or
PgR, or both, were significantly associated with outcome
[8]. The lack of consistent support for a single hormone
receptor, or for a single assessment method, precludes
focused application in clinical practice. Further, substan-
tive differences were noted with or without statistical
standardization of ER: respectively, qPCR ER, P = 0.12
versus 0.03; IHC ER, P = 0.21 versus 0.01; qPCR ER, P
= 0.11 versus 0.04. Differences in results by type of con-
tinuous unit support the concept that level of ER
beyond a dichotomous negative or positive stain is rele-
vant for medical decision-making. Further, we suggest it
is prudent at this time to consider that the conservative
indications of significance with standardized units are
appropriate. The literature is replete with transient indi-
cations of biomarker significance, such that the require-
ment for validation is now the norm.
We found that patients allocated to tamoxifen did not
exhibit significant multivariate ER or PgR effects on DFS,
nor were there significant hormone receptor effects when
patient data on both tamoxifen and placebo arms were
pooled. These results held for all patients and for those
with positive IHC ER and/or PgR stain, for qPCR and
IHC assessments, and with or without standardized units.
Table 1 NCIC CTG MA
IHC ER
P-
value1
IHC
PgR
P-
value1
qPCR
ER
P-
value1
qPCR
PgR
P-value1
Therapy
P-
value1
I. Placebo Arm
Cox Model for All
Patients:
All IHC values
IHC 0.27 0.08 N/A N/A N/A
Standardized IHC 0.96 0.07 N/A N/A N/A
qPCR N/A N/A 0.12 0.02 N/A
Standardized qPCR N/A N/A 0.12 0.02 N/A
IHC and qPCR 0.08 0.41 0.03 0.15 N/A
Standardized IHC and
qPCR
0.40 0.19 0.12 0.47 N/A
Cox Model for Patients
with
Positive IHC ER and/or
PgR
IHC 0.25 0.29 N/A N/A N/A
Standardized IHC 0.53 0.07 N/A N/A N/A
qPCR N/A N/A 0.23 0.01 N/A
Standardized qPCR N/A N/A 0.23 0.01 N/A
IHC and qPCR 0.01 0.67 0.04 0.01 N/A
Standardized IHC and
qPCR
0.21 0.50 0.11 0.04 N/A
II. Tamoxifen Arm
Cox Model for All
Patients:
All IHC values
IHC 0.18 0.61 N/A N/A N/A
Standardized IHC 0.44 0.89 N/A N/A N/A
qPCR N/A N/A 0.46 0.83 N/A
Standardized qPCR N/A N/A 0.46 0.83 N/A
IHC and qPCR 0.26 0.69 0.79 0.95 N/A
Standardized IHC and
qPCR
0.50 0.58 0.75 0.48 N/A
Cox Model for Patients
with
Positive IHC ER and/or
PgR
IHC 0.30 0.57 N/A N/A N/A
Standardized IHC 0.37 0.82 N/A N/A N/A
qPCR N/A N/A 0.22 0.19 N/A
Standardized qPCR N/A N/A 0.22 0.19 N/A
IHC and qPCR 0.75 0.57 0.34 0.20 N/A
Standardized IHC and
qPCR
0.67 0.14 0.22 0.07 N/A
III. Both Arms
Together
Cox Model for All
Patients:
All IHC values
IHC 0.20 0.45 N/A N/A 0.003
Standardized IHC 0.63 0.21 N/A N/A 0.004
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Chia et al. [2] did not observe differences in baseline
characteristics between the main MA.12 trial population
and those for whom there was central review of hormone
receptors. In the main trial, there was weak evidence
(P = 0.056) that tamoxifen improved DFS [11]. However,
trial therapy in the centrally reviewed population was
consistently associated with significant multivariate DFS
Table 1 NCIC CTG MA (Continued)
qPCR N/A N/A 0.66 0.20 0.004
Standardized qPCR N/A N/A 0.45 0.19 0.003
IHC and qPCR 0.07 0.75 0.15 0.48 0.002
Standardized IHC and
qPCR
0.28 0.22 0.20 0.99 0.003
Cox Model for Patients
with
Positive IHC ER and/or
PgR
IHC 0.18 0.43 N/A N/A 0.004
Standardized IHC 0.47 0.05 N/A N/A 0.005
qPCR N/A N/A 0.75 0.30 0.005
Standardized qPCR N/A N/A 0.75 0.30 0.005
IHC and qPCR 0.07 0.75 0.25 0.53 0.002
Standardized IHC and
qPCR
0.34 0.10 0.55 0.97 0.005
1P-value is for factor’s inclusion in stratified Cox model, with adjustment for
stratification factors of nodal status and adjuvant chemotherapy.
Figure 9 BC Cohort Disease Free Survival by Standardized qPCR
ER: Assay results are categorized by their z-scores (greater to or
equal to 1 standard deviation (SD) below mean, less than 1 SD below
the mean, less than or equal to 1 SD above the mean, and greater
than 1 SD above the mean). P-value is that for the generalized
Wilcoxon (Peto-Prentice) test statistic. ER, estrogen receptor.
Figure 10 BC Cohort Disease Free Survival by Standardized qPCR
PgR: Assay results are categorized by their z-scores (greater to or
equal to 1 standard deviation (SD) below mean, less than 1 SD below
the mean, less than or equal to 1 SD above the mean, and greater
than 1 SD above the mean). P-value is that for the generalized
Wilcoxon (Peto-Prentice) test statistic. PgR, progesterone receptor.
Figure 11 BC Cohort Disease Free Survival by Standardized
IHC ER: Assay results are categorized by their z-scores (greater to or
equal to 1 standard deviation (SD) below mean, less than 1 SD
below the mean, less than or equal to 1 SD above the mean, and
greater than 1 SD above the mean). P-value is that for the
generalized Wilcoxon (Peto-Prentice) test statistic. ER, estrogen
receptor; IHC, immunohistochemistry.
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(P = 0.002 to 0.005), in all centrally reviewed patients, and
in the subgroup of women whose tumours had positive
IHC stain for ER and/or PgR. The distribution of events in
patients with centrally reviewed tumors was not represen-
tative of the full trial population.
Our work was broadened here with a BC cohort of post-
menopausal patients, all of whom received adjuvant
tamoxofen, without adjuvant chemotherapy. The qPCR
and IHC assessments of ER and PgR were performed in
the same laboratory (that of TON). As in the MA.12 trial,
there was a general directional indication that univariate
DFS was better with higher ER and PgR, although there
appeared to be no difference after 10 years follow-up, and
overall there was no significant effect of ER or PgR on
DFS found by qPCR or IHC assay methods, with or with-
out statistical standardization. ER and PgR did not exhibit
significant multivariate effects on DFS, although there was
weak evidence (P = 0.06) that patients with higher qPCR
PgR had better DFS. We recognize the limitations in
cohort data, that patient and tumour characteristics could
have impacted clinical and patient decisions in treatment
choice, affecting outcomes. We also recognize that the
patient spectrum was reduced when only hormone recep-
tor positive patients are considered, and there was a deci-
sion not to administer adjuvant chemotherapy.
However, we note that there is some commonality for
this study as both MA.12 trial patients and the BC
cohort had qPCR and IHC assay results assessed in the
same laboratory. The juxtaposition of the MA.12 pre-
menopausal trial where patients with locally determined
hormone receptor positive and negative tumours were
randomized to receive tamoxifen or placebo, with the
BC postmenopausal patients who, with locally deter-
mined hormone receptor positive tumours, received
tamoxifen extends the spectrum of patients, tumour
characteristics, and experience. Both groups showed
general univariate directions that higher ER and PgR
were associated with better DFS. There was no multi-
variate evidence that ER and PgR had a significant prog-
nostic effect on DFS for either study population.
Inter-laboratory comparability of ER assay results has
been problematic for decades. A proposal in the early
1980s involved mathematical adjustment of laboratory
assay values utilizing reference laboratory values, like
the WHO mandated mathematical adjustment of pro-
thrombin times. Meanwhile, a lack of inter-laboratory
comparability for bone mineral density (BMD) was
resolved for both research and clinical purposes by the
WHO with mandated statistically standardized t-scores
and z-scores based on routine comparisons with refer-
ence population values.
Work on the proposal for adjunctive statistical stan-
dardization of ER began with poor inter-laboratory com-
parability in provincial quality control samples in the
late 1980s [6-10] with Ontario laboratories performing
biochemical ER assessments using the dextran-coated
charcoal radioligand method, continued after labora-
tories switched to the double monoclonal enzyme-
immunoassay, ER-EIA [7], and eventually, to immuno-
histochemical assays [8,9]. We hypothesized improved
inter-laboratory comparability of ER/PgR assay results
with adjunctive statistical standardization, and we
showed improved comparability with provincial quality
control samples, and examined the process in cohort
studies [6-10]. Continuous ER and PgR effects were
Figure 12 BC Cohort Disease Free Survival by Standardized
IHC PgR: Assay results are categorized by their z-scores (greater to
or equal to 1 standard deviation (SD) below mean, less than 1 SD
below the mean, less than or equal to 1 SD above the mean, and
greater than 1 SD above the mean). P-value is that for the
generalized Wilcoxon (Peto-Prentice) test statistic. IHC,
immunohistochemistry; PgR, progesterone receptor.
Table 2 BC POST-MENOPAUSAL COHORT: MULTIVARIATE
EFFECTS OF ER, PgR, ON DFS
IHC ER
P-value1
IHC PgR
P-value1
qPCR ER
P-value1
qPCR PgR
P-value1
IHC 0.76 0.31 N/A N/A
Standardized IHC 0.76 0.31 N/A N/A
qPCR N/A N/A 0.17 0.06
Standardized qPCR N/A N/A 0.17 0.06
IHC and qPCR 0.97 0.58 0.17 0.06
Standardized IHC and qPCR 0.97 0.58 0.17 0.06
1P-value is for factor’s inclusion in Cox model, with adjustment for significant
effects of age, number of positive nodes, and clinical T stage.
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indicated in time-to-event investigations with cohorts of
breast cancer patients [8,9]. The routine clinical use of
t-scores and z-scores for BMD demonstrates the feasi-
bility of adjunctive statistical standardization of ER and
PgR in breast cancer and suggests an approach that may
be clinically useful for delineating significant predictive
and prognostic effects of continuous ER and PgR at
multiple standard deviations below or above the mean.
Conclusions
The growth of many breast cancers is hormone-depen-
dent, with estrogen receptor (ER) and/or progesterone
receptor (PgR) expression a prerequisite for responsive-
ness to endocrine therapy. Increased awareness about
uncertainties in accurate assessment of these pivotal
breast cancer biomarkers has renewed interest in stan-
dardization; there is a potential that 20% of current IHC
assay results worldwide are either false negatives or false
positives [1].
We hypothesized that the process of statistical stan-
dardization, akin to bone mineral density (BMD) z-
scores, and originally envisaged to improve inter-labora-
tory comparability of ER/PgR assay results, might be
useful to improve comparability of results between
qPCR and IHC assay methods. We demonstrated statis-
tical standardization across assay methods in MA.12, a
placebo-controlled trial of adjuvant tamoxifen in preme-
nopausal women, with locally assessed hormone recep-
tor +/- tumours. We saw evidence suggestive of an
unspecified continuous prognostic effect for hormone
receptors. This is the first clinical trial report about sta-
tistical standardization in the unique MA.12 trial to
which premenopausal patients were accrued regardless
of their locally determined hormone receptor status.
Further, there was also directional evidence that BC
postmenopausal patients receiving tamoxifen had better
outcome in at least the first 10 years, when they have
higher hormone receptor assay values.
A plethora of laboratory assessment methods are used
to assess hormone receptors. We showed here in MA.12
that statistically standardized hormone receptors had
similar multivariate prognostic effects on DFS when
tumours were assayed by qPCR or by IHC, across a
spectrum of hormone receptor +/- tumours. The BC
cohort did not exhibit significant prognostic effects on
DFS for ER or PR, by qPCR or by IHC, with or without
statistical standardization. The process of statistical stan-
dardization would need to be laboratory specific, estab-
lished iteratively and cumulatively against external
quality assurance samples that cover the range of ER
and PgR assay levels. We are examining statistical stan-
dardization in other NCIC CTG endocrine trials.
The process of statistical standardization is akin to
BMD z-scores which are used in clinical practice, so it
would be feasible to consider statistically standardizing
hormone receptor assays.
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